Strategic Business Update Conference Call

January 17, 2023 – 4:30 PM ET

Latest Financial Results

Q3 2022

Quarter Ended Sep 30, 2022

Latest Annual Filing

For Fiscal Year Ending Dec 31, 2021

Company Overview

Lucid Diagnostics Inc., markets the first and only commercial tools for widespread early detection of esophageal precancer and cancer – the EsoGuard® Esophageal DNA Test and EsoCheck® Esophageal Cell Collection Device.

IR Contacts


Lucid Diagnostics Inc.
One Grand Central
60 East 42nd Street, Suite 4600
New York, NY 10165
T: 212-949-4319

Investor Relations

Michael Parks
Vice President of Investor Relations
M: 484-356-7105

Transfer Agent

Continental Stock Transfer & Trust Company
17 Battery Place
New York, NY 10004